or
Bookmark and Share
   
Document Number
US Patent 4320200
Issued Date
March 16, 1982
Link
Inventors
Map
Abstract
A novel Antibiotic C-15003 is produced by cultivating a microorganism of the genus Nocardia. The Antibiotic C-15003 is useful as an antifungal agent or an antiprotozoan agent.
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
1
Comments:
no comments yet
Published
March 16, 1982
Application Number
06/131,787
Filed
March 19, 1980
US Classification
435/253.2  
Int'l Classification
C07D   491/00   (20060101)   C07D   491/18   (20060101)   C07D   498/18   (20060101)   C07D   498/00   (20060101)   C12P   17/18   (20060101)  
Attorney/Law Firm
Parent Case
This is a division of application Ser. No. 972,492, filed Dec. 22, 1978, which in turn is a division of application Ser. No. 811,448, filed June 29, 1977, now U.S. Pat. No. 4,162,940.
Priority Data
Mar 31, 1977 [JP] 52-37166 Apr 01, 1977 [JP] 52-37886
USPTO Field of Search
435/119   435/128   435/872   435/253  
Related Patents
7264815 - Process for producing a recombinant protein in a mycobacterium host plasmid pJAM2 - Owned by Institut Pasteur (Paris,FR)

This invention relates to a novel mycobacterial protein named DES, which appears to share significant amino acid sequence homology with soluble stearoyl-ACP desaturases. The results of allelic exchange experiments, indicate that the des gene may be essential to the survival of mycobacteria. These results coupled with the surface localization, the unique structure of DES, and the fact this antigen is expressed in vivo, and DES protein induces a humoral response in human patients, indicate that the DES protein provides a new target for the design of anti-mycobacterial drugs. This invention provides methods of screening molecules that can inhibit the DES enzyme activity of purified DES protein, in order to identify antibiotic molecules that are capable of inhibiting the growth or survival of mycobacteria. These methods may be practiced by using recombinant DES protein obtained from a recombinant mycobacterium host cell that was transformed with a vector containing the des gene, whose expression is controlled by regulatory or promoter sequences that function in mycobacteria. Another aspect of this invention relates to the molecules that have been identified according to the screening methods as having antibiotic activity: against mycobacteria.

6573064 - Method of screening anti-mycobacterial molecules

This invention relates to a novel mycobacterial protein named DES, which appears to share significant amino acid sequence homology with soluble stearoyl-ACP desaturases. The results of allelic exchange experiments, indicate that the des gene may be essential to the survival of mycobacteria. These results coupled with the surface localization, the unique structure of DES, and the fact this antigen is expressed in vivo, and DES protein induces a humoral response in human patients, indicate that the DES protein provides a new target for the design of anti-mycobacterial drugs. This invention provides methods of screening molecules that can inhibit the DES enzyme activity of purified DES protein, in order to identify antibiotic molecules that are capable of inhibiting the growth or survival of mycobacteria. These methods may be practiced by using recombinant DES protein obtained from a recombinant mycobacterium host cell that was transformed with a vector containing the des gene, whose expression is controlled by regulatory or promoter sequences that function in mycobacteria. Another aspect of this invention relates to the molecules that have been identified according to the screening methods as having antibiotic activity against mycobacteria.

7067136 - Method of screening anti-mycobacterial molecules - Owned by Institut Pasteur (Paris,FR)

This invention relates to a novel mycobacterial protein named DES, which appears to share significant amino acid sequence homology with soluble stearoyl-ACP desaturases. The results of allelic exchange experiments, indicate that the des gene may be essential to the survival of mycobacteria. These results coupled with the surface localization, the unique structure of DES, and the fact this antigen is expressed in vivo, and DES protein induces a humoral response in human patients, indicate that the DES protein provides a new target for the design of anti-mycobacterial drugs. This invention provides methods of screening molecules that can inhibit the DES enzyme activity of purified DES protein, in order to identify antibiotic molecules that are capable of inhibiting the growth or survival of mycobacteria. These methods may be practiced by using recombinant DES protein obtained from a recombinant mycobacterium host cell that was transformed with a vector containing the des gene, whose expression is controlled by regulatory or promoter sequences that function in mycobacteria. Another aspect of this invention relates to the molecules that have been identified according to the screening methods as having antibiotic activity, against mycobacteria.

4450234 - Antibiotic C-15003 PHM and production thereof - Owned by Takeda Chemical Industries, Ltd. (Osaka,JP)

Novel antibiotic C-15003 PHM, which is produced by cultivating a microorganism belonging to the genus Nocardia and being capable of producing antibiotic C-15003 PHM, and novel C-15003 PHM acylate, which is produced by subjecting C-15003 PHM thus obtained to acylation reaction with an acylating agent, have antiprotozoan and antitumor activities.

Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us